Mesoblast Limited
Mesoblast Limited (MESO) Revenue
Annual & quarterly revenue history · segment & region breakdown
MESO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMesoblast Limited trailing twelve-month (TTM) revenue is $0.02B, an increase of 191.39% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-06-30 | $0.02B | +$0.01B | +191.39% |
| 2024-06-30 | $0.01B | -$0.00B | -21.32% |
| 2023-06-30 | $0.01B | -$0.00B | -26.54% |
| 2022-06-30 | $0.01B | +$0.00B | +36.95% |
| 2021-06-30 | $0.01B | -$0.02B | -76.81% |
| 2020-06-30 | $0.03B | +$0.02B | +92.30% |
| 2019-06-30 | $0.02B | -$0.00B | -3.57% |
| 2018-06-30 | $0.02B | +$0.01B | +618.95% |
| 2017-06-30 | $0.00B | -$0.04B | -94.33% |
| 2016-06-30 | $0.04B | +$0.02B | +79.16% |
Compare revenue vs peers
BiotechnologyCompare MESO revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Mesoblast Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Mesoblast Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Mesoblast Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MESO revenue · 4 questionsMESO's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 191.39% year-over-year from $0.02B in FY2025.
▸ Source: FMP · Mesoblast Limited SEC filings · GAAP · Mesoblast Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026